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Cancer as a Metabolic Disease
Javaria Haseeb
Department of Biochemistry, Merrimack College, North Andover MA 01845, USA

Abstract
Despite decades of intensive scientific and medical efforts to develop efficient and
effective treatments for cancer, it remains one of the prime causes of death today. For example,
in 2016, there will be an estimated 1,685,210 new cases of cancer and 595,690 deaths due to
cancer in the United States alone (National Cancer Institute). Worldwide in 2012, there were an
estimated 14 million new cases of cancer and 8.2 million deaths due to cancer. In order to come
up with better methods of detection and more successful modes of treatment, it is crucial that
scientists understand the depth of not only what causes cancer but also what sustains it. This
literature review examines cancer as a metabolic disease. More specifically, it summarizes
carbohydrate metabolism and compares and contrasts the roles of the glucose transporter, the
metabolic enzymes hexokinase, pyruvate kinase, citrate synthase, succinate dehydrogenase,
cytochrome c oxidase, ATP synthase, and the tumor suppressor protein p53 in normal versus
cancer cells. The review focuses on the altered cellular function of these molecules and the
significance of their dysfunctionality in the transformation of normal to cancer cells.
Introduction
Research has established that cancer
is not a single disease but multiple diseases
and epigenetic change contributes to its
formation (Hirschey et.al, 2015). Cancer is
characterized by unrestrained cellular
proliferation, which may arise from nuclear
genetic mutations or from mitochondrial
DNA damage which alters the metabolic
pathways – a network of chemical reactions
either building (anabolism) or breaking
(catabolism) molecules in an organism – of
a cell.
The hallmarks of cancer comprise
six biological functions acquired during the
development of human tumors, which
include: 1) cell proliferative signals; 2)
evading growth suppressors (also known as
tumor suppressors); 3) inhibition of

apoptosis (cell death); 4) enabling
replicative immortality; 5) inducing
angiogenesis and 6) activating invasion and
metastasis. Conceptual progress in the last
decade has added two emerging hallmarks to
this list: evading immune destruction and
reprogramming of energy metabolism
(Weinberg & Hanahan, 2011)
This review focuses on several
differences
in
carbohydrate
energy
metabolism between normal and cancer cells
and their significance in the cause and/or
maintenance of the malignant phenotype.
Carbohydrate metabolism comprises the
different biochemical processes responsible
for
anabolism
and
catabolism
of
carbohydrates in an organism. Glycolysis
and the citric acid cycle are two of the many
biochemical processes used by cells for the
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catabolism of glucose molecules, which are
ultimately converted into useable energy in
the form of ATP. Normal cells produce up
to 32 ATP molecules per glucose molecule
oxidized through glycolysis, citric acid
cycle, and oxidative phosphorylation. 2 ATP
molecules are produced from glycolysis in
the cytosol and the other 30 in the oxidative
phosphorylation using NADH and FADH2
generated from glycolysis and the citric acid
cycle.
In the 1920s, Dr. Otto Warburg first
observed the glucose metabolism in normal
vs. cancer cells. He observed that the
amount of glucose uptake in cancer cells
was significantly greater than that in normal
cells. He also observed that while normal
mammalian cells usually convert all of their
glucose into pyruvate via glycolysis, cancer
cells converted more than half of their
glucose into lactate (M.D. Hirschey et.al,
2015) in the presence or absence of oxygen
(Bensinger & Christofk, 2012). This effect is
known as the Warburg effect (Bensinger &
Christofk, 2012). However, the mechanism
of how cancers do this is yet to be
determined.
One metabolic aberration in cancer
cells includes a broken link between
glycolysis and the oxidative phosphorylation
(OP). OP is oxygen dependent whereas
glycolysis is oxygen independent. Cancer
cells take advantage of glycolysis being
independent of oxygen and thus excel it,
breaking the homeostatic link between
glycolysis and OP. The rate of ATP
production in cancer cells is 100 times faster
than that of normal cells. Thus, even by
taking an insufficient pathway for ATP
production, cancer cells are able to
proliferate at high rates. Where normal cells
are strategically programmed to work

together to build various types of tissues
needed for organismic survival, cancer cells
have a different agenda. All they want to do
is make more copies of themselves and the
Warburg effect helps them with that
(Weinberg, 2014).
1. Glucose transport
Normal and cancer cells alike need
glucose for survival. Our cells acquire
glucose from the blood stream via
transporters located on the cell’s membrane.
The glucose transporters (GLUT) are a
group of 14 different uniporter membrane
proteins that transport glucose through the
plasma membrane into the cell. GLUT-1,
which is encoded by the SLC2A1 gene in
humans, is of primary importance to this
review (Serra et.al, 2014). In normal cells,
the level of GLUT-1 on the membrane
fluctuates depending on how much glucose
is available in the blood stream, such that
the GLUT-1 level is inversely proportional
to glucose level. However, it has been
observed that GLUT-1 is expressed in high
levels in many tumors, regardless of the
level of glucose present in the blood stream
(Serra et.al, 2014). This allows for an
increase in glucose uptake to serve the high
energy demands of cancer cells (i.e, rapid,
uncontrolled cell division). High levels of
GLUT-1 are also found in fetal tissues, adult
erythrocytes,
and
endothelial
cells.
Interestingly, cancer cells are known to
mimic fetal and undifferentiated cells in
many ways.
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2. Glycolysis
Once glucose enters the cytosol, it can
undergo oxidation by glycolysis, a series of
10 enzyme catalyzed chemical reactions in
which glucose is broken down to two
pyruvate molecules (as shown in Fig.2).
Energy is required in the first half of the
process and then generated in the second
half. For each glucose molecule, 2
molecules of pyruvate, 2 NADH, and 2 ATP
molecules are generated (Pratt & Cornely,
2014).

Fig. 1: Difference in Metabolism between Normal
vs. Cancer cells. The figure shows the glucose
metabolic pathway in a) a normal cell and b) in
cancer cell. In a) a normal cell, glucose is transported
into the cell via GLUT-1 where catabolism takes
place through glycolysis, where glucose is committed
to catabolism by HK (not shown) and broken down in
to pyruvate by PKM-1. 2 ATP molecules are
generated in this process. Pyruvate is then transported
in to the mitochondria where it is converted to acetylcoA which goes through the citric acid cycle. The
NADH and FADH2 generated from glycolysis and
citric acid cycle goes through oxidative
phosphorylation (OP) through which the proton
gradient (not shown) is established, O2 is reduced to
form water, and 32 ATP molecules are synthesized.
Increase levels of P53 (refer to 5. P53) inhibits
glycolysis when necessary blocking glucose
metabolism with no net ATP production. In b) cancer
cell, glucose is transported in the cell via GLUT-1
where catabolism takes place through glycolysis,
where glucose is committed to catabolism by HK2
(not shown) and broken down in to pyruvate by
PKM-2. Pyruvate is then converted to lactate by LDH
and leaves the cell creating an acidic environment
(not shown). The chain between glycolysis and OP is
broken (marked as red) and P53 is either silenced or
completely lost from the cell.

Fig.2: Glycolysis. A series of 10 enzyme catalyzed
chemical reactions in which glucose is broken down
to two pyruvate molecules. There is a preparatory
phase where two ATP molecules are consumed and a
payoff phase where 4 ATP and 2 NADH molecules
are generated, producing a total of 2 ATP, 2 NADH,
and 2 Pyruvate molecules in the end (Giri, 2016).
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Hexokinase
Hexokinase (HK) catalyzes the first
step of glycolysis in the cytosol (in most
glycolytic pathways) converting glucose to
glucose-6-phosphate (G6P). This is a ratelimiting step for glycolytic pathway, which
commits glucose molecules to undergo
complete oxidation (Bioinformatics, 2016).
The role of HK in committing glucose
molecules to energy metabolism may play a
crucial role in supporting cancer, since these
cells require an abundance of glucose energy
for survival. HK is an enzyme located on the
outer membrane of mitochondria, which is
expressed in four isoforms, HK1, HK2,
HK3, and HK4 all of which are found in
humans (Patra, et.al 2013). HK1 is common
in various types of cells in adults, HK4 is
common in liver and pancreatic cells, little is
known about HK3, and high levels of HK2
have been observed in many types of cancer
including epithelial ovarian, breast, and
colon cancer.
HK2 has two catalytic domains, the
N- and C-terminals (Ahn et.al, 2009). Both
domains have enzyme activity with Nterminal having a higher activity than the Cterminal. Even though there are two binding
sites for glucose on HK2, only one molecule
binds at a time. Studies suggest that when
one glucose molecule binds on one of the
two sites, it causes the enzyme to go through
a conformational change, which then
prevents another glucose molecule from
binding to the enzyme during catalysis
(Cardenas et.al, 1998). It is not completely
known why HK2 has two glucose binding
sites when it only catalyzes one molecule at
a time.
High levels of HK2 are of great
significance to cancer cells as observed in

many different studies. In one of the studies,
tissues of 48 colorectal cancer patients were
studied for mRNA expression of proteins
including but not limited to HK2, GLUT-1,
PKM2, and VDAC-1 (Graziano et.al, 2016).
Significantly high levels of these proteins
were observed in primary tumor and liver
metastasis with respect to the levels in
normal mucosa. Other experiments have
shown enhanced glycolytic rate when
solubilized HK2 was added in a liver tumor
cytosol (Hirschey et.al, 2015). In mouse
models of kRas-driven lung cancer and Erbdriven breast cancer, HK2 was shown to be
necessary to initiate and maintain tumor
cells (Patra et.al, 2013).
Studies have shown a correlation
between low levels of HK2 and downregulation of the Warburg effect (a decrease
in the rate of glycolysis). In one study of
epithelial ovarian cancer (EOC), low levels
of Glucose transporter 1 (GLUT1), HK2,
and down-regulation of the Warburg effect
and cell proliferation were observed when a
transcription factor known as FOXM1 gene
expression was suppressed (Wang et.al,
2016). FOXM1 bind directly to the promoter
region of GLUT1 and HK2 gene and
promotes synthesis at the transcriptional
level, so when FOXM1 was knocked down,
the levels of GLUT1 and HK2 were
observed to decrease (Wang et.al, 2016). In
another study, the inhibition of HK2 was
shown to improve the effects of anticancer
drugs (Peng, et.al, 2009). Thus high levels
of HK2 may very well be involved in the
alteration of cancer cell’s metabolism and
the transformation of normal cells into
cancer cells. The mechanism of how HK2
may be involved in tumorigenesis, however,
is still unknown.
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Pyruvate Kinase
Pyruvate Kinase catalyzes the last
step in glycolysis where it converts
phospenolpyruvate (PEP) and ADP to
pyruvate and ATP. This is another rate
limiting step in the glycolytic path after
HK2 (Bensinger & Christofk, 2012). The
PKM gene encodes for isoenzymes PKM1
and PKM2. They are located in the cytosol
within the glycolytic enzyme “complex”.
The two isoforms only differ in 23 amino
acids within a 56 amino acid band on the Cterminus. PKM1 is commonly found in
normal cells and assures the import of
pyruvate in to the mitochondria, whereas
PKM2 is active in embryos and more
common in tumor cells where it diverts
pyruvate to lactate dehydrogenase-A (LDHA), which reduces pyruvate to lactate. Our
focus is on PKM2 which is expressed in
organs with high energy demands such as
muscle, brain, and all cells that have high
rate of nucleic acid synthesis, such as
normal proliferating cells, embryonic cells,
and tumor cells (Gupta & Bamezai, 2010).
PKM2 is present in two forms,
tetrameric and dimeric. The tetrameric form
has high affinity to PEP and is highly active
at physiological PEP concentration, whereas
the dimeric form has low affinity to PEP and
is almost inactive at physiological PEP
concentration. The dimeric form of PKM2,
termed as Tumor M2-PK, is observed in
many tumor cells (Mazurek, et.al, 2005). An
increase in glycolysis helps to meet energy
demands of high synthesis in cancer cells
and PKM-2 plays an important role in
generating synthetic intermediates. The low
tetramer to high dimer ratio of PKM2 effects
the conversion of glucose. High levels of
dimeric form of PKM2 favors the
conversion of glucose to lactate, whereas the

tetrameric form favors the conversion of
glucose to pyruvate.
The alteration of normal enzymes
within the glycolytic complex hinders how
the intermediates are processed. The shift
from oxidative phosphorylation to glycolysis
for ATP production with feedback inhibition
accelerates glycolysis, which leads to
enhanced lactate production. Glycolysis
becomes the fastest way for energy
production as well as the best pathway to
synthesize
nutrients
(that
are
the
intermediates) to help with cell proliferation.
(Icard, 2011).
In one study that investigated the
effects of PKM2 expression in osteosarcoma
(Liu, et.al, 2016); PKM2 expression was
observed to be elevated in cancerous tissues
with respect to the adjacent normal tissues.
The same study also showed an overall
decrease in patient survival rate in the
presence of high PKM2 levels than low
PKM2 levels. In another study, silencing of
PKM2 was shown to increase docetaxel (a
chemotherapy drug) sensitivity in cells
leading to strong suppression of cell
viability (Yuan, et.al, 2016). High levels of
PKM2 can be detrimental for patients and
inhibition may increase the survival rate.
This suggests the great importance of PKM2
levels present in cancer cells.
Other experiments have also shown that
the growth of tumors depend on PKM2
expression, high levels of GLUT-1, and
LDH-A. Inhibition of either of these
proteins have been observed to noticeably
slow
down
tumor
growth.
These
observations show that the altered glucose
metabolism of cancer cells creates a
physiological system favorable for cancer
growth and proliferation (Weinberg, 2014).
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3. Citric Acid Cycle

Citrate Synthase

Citric acid cycle, also known as the
Tricarboxcylic acid (TCA) or krebs cycle, is
a pathway located in the inner matrix of
mitochondria. When pyruvate enters the
mitochondria it is converted into acetyl-coA, which then proceeds in the TCA cycle,
producing 2 CO2, 3 NADH, 2 FADH2, and 1
ATP molecule. Note that amino acids, fatty
acids, and carbohydrates can enter the cycle
and go through the same process as well.
The cycle is a series of enzyme catalyzed
chemical reactions (as shown in Fig. 3),
where the intermediates can serve as
precursors of many reactions and products
of different biological molecules (Pratt and
Cornely, 2014).

Citrate synthase (CS) is an enzyme
in the first step in the citric acid cycle
(commonly assumed to be the rate limiting
step) in which it catalyzes the condensation
reaction of acetyl-coA and oxaloacetate to
citrate. It is located in the mitochondrial
matrix, transcribed by the nuclear DNA, and
serves as a central enzyme in the process of
glucose oxidation. It is comprised of 437
amino acids, which are organized into two
subunits with 20 alpha helices each. Three
quarters of the helices have tertiary structure
while the remaining have irregular structure
and a beta sheet composed of 13 amino acid
residues. The active site is roughly located
between the two subunits where each
subunit has a binding site, one for acetylcoA and the other for oxaloacetate
(http://pdb101.rcsb.org/motm/93).
High
levels of ATP:ADP, acetyl-coA:CoA, and
NADH:NAD ratio inhibit CS; these signal
that the cell has enough energy and does not
need to generate more energy until the ATP,
acetyl-coA, and NADH levels decline.

Fig.3: Citric Acid Cycle. The cycle is a series of
enzyme catalyzed chemical reactions that take place
in the mitochondria to catabolize pyruvate. The
intermediates can serve as precursors of many
reactions and products of different biological
molecules (not shown). 2 CO2, 1 ATP, 3 NADH, and
2 FADH2 molecules are generated
(http://www.chemistrylearning.com/krebs-cycle/).

The catalysis of the condensation
reaction of acetyl-coA and oxaloacetate to
citrate by CS means that CS activity is
proportional to citrate concentration.
Increase in CS activity will yield high levels
of citrate, which has shown anti-cancer
properties that sensitize cancer cells to
chemotherapy (Icard, et.al, 2012). In normal
cells, the Pasteur Effect – the process of
fermentation inhibited in the presence of
oxygen (opposite of the Warburg effect) – is
regulated by ATP and citrate. Under
hypoxic conditions, the cell undergoes
oxidative stress that results in low level of
ATP and citrate in the mitochondria. This in
turn
increases
the
activity
of
phosphofructokinase-1 (PFK1) – the enzyme
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catalyst in the third step of glycolysis –
which in turn increases the rate of glycolysis
to generate sufficient energy to keep the cell
alive (Icard, et.al, 2012).
Alterations in CS activity have been
observed in many types of cancers (Chen
et.al, 2014). In a study of ovarian carcinoma,
the cell line of benign tumor was compared
with normal human ovarian surface
epithelium, and ovarian tumor cell line was
compared with ovarian cancer cell line
(Chen et.al, 2014). High levels of CS were
observed in benign versus normal and
tumors versus cancer cell line. These
observations show the proportionality
between cell transformation and CS levels
and suggest that CS expression is correlated
with tumor progression. It has also been
observed that the knock down of CS in
ovarian cancer cell lines slowed down the
process of cell proliferation and inhibited
invasion and migration of cancer cells in
vitro. The knock down also helped sensitize
cancer cells to chemotherapeutic drugs like
cisplatin, which subsequently showed
enhanced apoptotic results (Chen et.al,
2014). In another study, however, the effects
of knocked down CS were analyzed in
human cervical cancer cell lines in which
the silencing of CS showed an increase in
cell proliferation, invasion, and migration in
vitro (Lin, et.al, 2012). The metabolic shift
of normal cells to cervical tumor cells was
observed and results showed that low levels
of CS corresponded to the switch from
normal aerobic respiration to glycolysis
(Lin, et.al, 2012). The contradiction
regarding the effects of CS activity in
different types of cancer is one of the many
examples demonstrating that cancer is not a
single disease but multiple diseases with
distinct alteration in metabolism that thus
require different treatments.

It is interesting to note how CS activity
regulated in normal cells under hypoxic
conditions resembles the activity in cancer
cells. The majority of tumor cells are found
to be hypoxic and exhibit the same kind of
behavior, which is catabolizing glucose in to
higher yields of lactate than pyruvate.
Succinate Dehydrogenase
Succinate Dehydrogenase (SD) is
one of the many tumor suppressor protein
(encoded by a tumor suppressor gene, which
regulates cell cycle by slowing down cell
division, repairing DNA, and inducing
apoptosis when necessary) located on the
inner membrane of the mitochondria (King
et al, 2006). It is involved in both, the citric
acid cycle and the oxidative phosphorylation
(OP) also known as the electron transport
chain (ETC), which will be discussed later
in this review. SD catalyzes step 7 of the
citric acid cycle and is also known as
complex II in OP where it couples the
oxidation of succinate to fumarate in the
citric acid cycle with the reduction of
ubiquinone to ubiquinol in OP. Mutations in
SD are found to promote cancer
transformation through the production of
carcinogens (Ciriolo & Cardaci, 2012). The
mechanism and detailed effects of SD in
cancer
metabolism
is
still
under
investigation.
4. Oxidative Phosphorylation
Oxidative Phosphorylation is the main
source of ATP production in normal cells. It
is the final stage of catabolism of metabolic
fuels, a process whereby free energy from
the transfer of electrons is conserved in a
transmembrane gradient of protons that is
then used to power ATP synthesis (Pratt &
Cornely, 2014). The OP pathway is
comprised of 5 complexes as shown in
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Fig.4, two of which are of particular
significance in cancer cell metabolism.

Fig.4: Oxidative Phosphorylation. There are five
complexes involved in oxidative phosphorylation
located in the inner mitochondrial membrane space.
Complexes I-IV are in sequence on the right and
complex V is shown on the left. Complexes I and II
take the electrons from NADH and FADH 2 generated
from the citric acid cycle and pass it on to complex
III and IV through ubiquinone and cytochrome c.
During this process, protons are pumped from the
matrix into the intermembrane space creating a
proton gradient. Complex V then utilizes the proton
gradient to synthesize ATP from ADP and Pi
(https://www.khanacademy.org/science/biology/cellu
lar-respiration-and-fermentation/oxidativephosphorylation/a/oxidative-phosphorylation-etc).

Cytochrome c oxidase (Complex IV)
Cytochrome c oxidase (COX), also
known as complex IV, is a large
transmembrane protein located on the inner
membrane of mitochondria. It is the central
part of the oxidative phosphorylation
metabolic pathway where oxygen is
reduced. In mammals, it is composed of 13
subunits, 10 of which have a nuclear origin
and the other three have a mitochondrion
origin (Krieg, et.al, 2004). Each complex
has multiple metal prosthetic groups that are
integral to the electron transfer process.
There are two hemes present on the
complex, one of which forms a binuclear
center (a3-CuB) that carries out oxygen

reduction. Four cytochrome c molecules
transfer 4 electrons, one at a time, to CuA,
which passes the electrons to cytochrome,
and then on to the binuclear center where
oxygen is reduced and 2 water molecules are
formed. During this process, COX attracts 8
protons, 4 of which are used in the
formation of water molecules and the other
4 are pumped out in the intermembrane
space enhancing the protein gradient (Pratt
& Cornely, 2014).
COX
is
present
in
three
configurations: fully oxidized (also known
as pulsed), partially reduced, and fully
reduced. Different types of inhibitors have
affinity towards different conformational
states. Cyanide, for example, is a
competitive inhibitor and has a high affinity
to the partially reduced state of COX. It
binds slowly but efficiently to binuclear site
when the complex is in that state. On the
other hand, high levels of ATP can
allosterically inhibit cytochrome c oxidase
(Arnold & Kadenbach, 1997).
Since COX is a central part of the
oxidative metabolism, an alteration in this
enzyme may have proportional effects on
alterations in metabolism seen in cancer
cells (Krieg et.al, 2004). In cancer cells, the
homeostasis between the glycolytic pathway
and oxidative phosphorylation is disrupted.
The high level of glycolysis is used to
acquire immense level of ATP production
and the cell is not dependent on oxidative
phosphorylation (OP) to fulfill its energy
needs, unlike normal cells. Studies have
shown an increase in the level of nuclear
encoded versus mitochondrial encoded COX
subunits in tumor derived cell lines of
prostate and urothelial epithelium (Krieg
et.al, 2004). High activity of COX was also
observed in these cell lines and was
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correlated with an increase in glycolysis.
High activity of COX is thought to assist
tumor by depleting the citric acid cycle
intermediates, which will lower the citrate
concentration so it cannot inhibit PFK,
therefore creating an environment that
favors high rate of glycolysis (Krieg et.al,
2004). Further research needs to be done to
understand the correlation between the COX
proteomics and its link to metabolic
alteration.
Another study has shown the
correlation between altered COX function
and the Warburg effect, a hallmark of
metabolic reprogramming. In this study, two
of the 10 nuclear encoded COX subunits,
IVi1 and Vb were knocked down to disrupt
the COX normal function (Srinivasan et.al,
2016). These cytochrome c oxidase knock
down (COXKD) cells showed a loss of
COX activity, which was linked to the
metabolic switch to glycolysis. The knock
down of either subunit showed an increase
in HK and phosphofructokinase (PFK) in
cells. This led to an increase in glucose
consumption and GLUT4 mRNA levels by
greater than 2 folds compared to normal
cells. However, the level of GLUT-1 was
not affected, which is quite interesting as
GLUT-1 is found in high levels in many
cancer types. All these observations show a
link between the disrupted COX and
metabolic reprogramming in cancer cells.
The COXKD cells were observed to have
invasive phenotype, a decrease in
transmembrane potential, and upregulation
of genes that regulate cell growth, motility,
invasiveness, and other hall marks of cancer
cells. The induction of tumorigenesis may
potentially be caused by defected COX,
which may very well be used as a biomarker
(Srinivasan et.al, 2016).

ATP Synthase (Complex V)
ATP Synthase (ATPs), also known
as complex V, is a part of the OP metabolic
pathway. It is involved in the catalysis of
ATP
synthesis
by
forming
phosphoanhydride bond between ADP and
Pi, as well as in the decomposition of ATP
to ADP and Pi, and thus serves as the rate
limiting step in OS (Whitford, 2005). ATPs
is located on the inner membrane of
mitochondria and has two domains, Fo and
F1, both of which are known to have
different biological and chemical properties.
Fo is the hydrophobic domain embedded in
the inner mitochondrial membrane where it
functions as a proton translocator using the
proton gradient created by the electron
transport chain. F1 is the hydrophilic domain
located in the mitochondrial matrix and
consists of 5 different subunits. Fo and F1
domains of ATPs work together by using the
energy generated from the proton gradient to
form or break the phosphoanhydride bonds
for the synthesis or decomposition of ATP
(Whitford, 2005).
ATPs plays an important role in
human carcinoma, and its malfunction is
known to be involved in mediation and
progression of different types of human
pathologies (Cenizo et.al, 2010). Studies
have shown the importance of ATPs and
how the malfunctioning could contribute in
carcinogenesis. In normal cells, a protein
known as inhibitory factor 1 (IF1) is known
to prevent ATPs from shifting to ATP
hydrolysis under hypoxic conditions. The
expression of IF1 varies among different
tissues, as it is highly expressed in heart,
moderately in liver, and almost negligible in
breast, colon, and lung. In human
carcinoma, studies have shown that IF1 is
found in abundance even in the cells that
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once had negligible levels. This resulted in
the malfunctioning of ATPs and promoted
the switch to high rates of aerobic
glycolysis. As expected, the silencing of IF1
was shown to have reverse effects as it
decreased the rate of glycolysis (Arago et.al,
2012). What causes the upregulation of IF1
is still unknown. One may wonder what
causes IF1 to not interfere with ATPs
activity when it is highly expressed in
normal tissues such as the heart. It is
hypothesized that perhaps the IF1 protein
goes
through
post-translational
modifications which do not allow it to
interfere with normal ATPs activity and
perhaps that modification is subdued in
carcinoma (Arago et.al, 2012).
In another study, elevated expression of
IF1 was shown to be involved in mediating
the switch to Warburg phenotypes by
regulating tumor metabolism through ATPs
activity. Monoclonal antibodies were used
against IF1 to show high expression of IF1
in human carcinomas compared to normal
cells and high levels were shown to increase
the rate of aerobic glycolysis with a decrease
in OP. The silencing of IF1 had the opposite
effects as a decrease in the rate of aerobic
glycolysis and an increase in the rate of OP
was observed. These observations were
correlated to the Warburg effect in this study
(Cenizo et. al, 2010).
5. P53
P53, also known as TP53, is a wellknown tumor suppressor encoded by a
tumor suppressor gene. A tumor suppressor
gene is an anti-oncogene that regulates cell
cycle by slowing down cell division,
repairing DNA, and inducing apoptosis
when necessary. One of the hallmarks of

cancer cells is its ability to evade tumor
suppression (Weinberg & Hanahan, 2011).
P53 gene is located on chromosome
number 7 and it is a phosphoprotein with
393 amino acids that build its 4 domains
(Bioinformatics). Each domain has a distinct
function to activate transcription factors,
recognize
specific
DNA
sequences,
tetramerize the protein, or recognize DNA
damage.
P53 also regulates mouse double minute
2 (Mdm2), also known as E3 ubiquitinprotein ligase, encoded by the Mdm2 gene,
and uses it to regulate its own levels. P53
proteins that are not phosphorylated binds to
Mdm2, which then degrades it through
ubiquitination (Bioinformatics). P53 helps
maintain the cell’s genome stability by
preventing mutations through regulating
DNA damage repair proteins (Jones
&Thompson, 2009). Low levels of P53 are
present in normal cells which are activated
and increased if the cell has been insulted
with DNA damage, hypoxia, and oxidative
stress, shunting the cell to go under
apoptosis (Jones & Thompson, 2009).
With the tumor suppressor functions,
P53 also has an important role in terms of
metabolism. It has the ability to reduce the
glycolytic flux, thus oppose the Warburg
effect
(Hirschey,
et.al,
2015).
Approximately 50% of all tumors have
mutations in p53 (Bioinformatics).
Energy homeostasis pathways are
regulated by stress-induced transcriptional
programs, which in turn are regulated by
p53 (Jones & Thompson, 2009). When a cell
goes under hypoxia induced oxidative stress,
the
level
of
(cyclic
adenosine
monophosphate) cAMP:ATP increases
which
activates
5’
adenosine
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monophosphate-activated protein
kinase
(AMPK), which then not only activates p53
but also inhibits lipid and protein synthesis,
crucial for cell growth. The increase in p53
then triggers a protein called TIGAR (TP53inducible
glycolysis
and
apoptosis
regulator), which inhibits the glycolytic
pathway.

behave abnormally (Jones & Thompson,
2009). The silencing or complete loss of P53
allows the switch in the metabolism from
OP to glycolysis without blocking the cell
cycle and inducing apoptosis.

Studies have also shown that the activity
of P53 favors the formation of ATP from
OP, which is common in normal cells (Jones
& Thompson, 2009). It does this by
regulating fructose-2-6-biphosphate (in the
glycolytic pathway), TIGAR, and the
assembly of COX by cytochrome c oxidase
assembly protein (SCO2). It is interesting to
note that a lack of SCO2 assists the cell to
shift from OS to glycolysis to generate ATP
(Jones & Thompson, 2009).
Another study has shown an interesting
relationship between PKM2 and p53. An
increase in PKM2 resulted in a decrease in
p53 protein level with a short half-life (Wu,
et.al, 2016). However, when PKM2 was
knocked down in the cell, the p53 level
increased with a greater half-life. It was also
observed that PKM2 is capable of directly
binding to p53 and MDM2 complex and
promote p53 ubiquitination (dimeric form of
PKM2 has a greater significance) (Wu, et.al,
2016).
Defects or a loss in P53 results in
abnormal cell proliferation, which is one of
the hall marks of cancer. This provides a
great growth opportunity for normal cells to
transform in to cancer cells. When normal
cells are insulted with multiple DNA
damage, hypoxic oxidative stress, and other
cell insults, the absence of p53 would mean
the absence of repair mechanism and
apoptosis induction, allowing the cell to

Table. 1: Compares the significance of GLUT-1,
HK, PKM, SD, CS, COX, ATPs, and P53 in cancer
verses normal cells.

Conclusion
All that is known about cancer and
the advances in treatment seen today have
been a direct result of a terrifying historical
background. It was an era of trial and error
in the scientific community where thousands
of cancer patients had no choice but to go
through treatments that were nothing more
than an educated guess from doctors and
scientists. The patients ended up having
severe side effects, making the approach to
death as horrific as it could be. The trials
ranged from directly injecting toxins in
patients with no knowledge of dosage and
side effects, to performing radical
mastectomy with no knowledge of what
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cancer actually is and how it metastasizes. It
is important to note, however, that all of this
was done with an intention to save lives
because the rate of patients coming in with
cancer was increasing and scientists did not
understand what cancer is, let alone know
how to cure it. (Mukherjee & Burns, 2015).
Research in mitochondria has
enabled us to discover the differences in the
structure and function of this organelle
between normal and cancer cells. These
differences have been used to develop novel
site-specific targets for chemotherapy.
Mitochondria-targeted
drugs
or
mitochondria-anticancer agents (mitocans)
have shown both efficacy and selectivity to
kill cancer cells in pre-clinical and early
clinical trials. However, these drugs as
single agents are not yet sufficient to go
beyond phase III clinical trials, which
requires high selectivity, efficacy, and low
toxicity (Napolitano & Weissig, 2015). This
challenge has led scientist to come up with
new strategies to enhance the selectivity of
mitocans to achieve the desired results in
vitro and vivo.
Further research on mitochondria
and targeting it for cancer therapies will
undoubtedly lead to new drug discoveries
and new methods that will enable us to
create more efficient and selective
treatments for a variety of cancers. Perhaps
it may take another era to ultimately save all
the lives suffering from cancer, but progress
is what gives us hope and the battle against
cancer will continue.

Acknowledgements
Primary Advisor: Dr. Josephine S.
Modica-Napolitano, Professor in the

Department of Biology, Merrimack College,
North Andover, MA 01845, USA.
References
1. Ahn, K., Kim, J., Yun, M., Park, J.,
Lee, J., 2009. Enzymatic Properties
of the N- and C-terminal Halves of
Human Hexokinase II. Korean
Society for Biochemistry and
Molecular Biology.
2. Argo,
M.S.,
Formentini,
L.,
Bermudez, J.C., Cuezva, J.M., 2012.
IF1 reprograms energy metabolism
and signals the oncogenic phenotype
in cancer. Cell Cycle. 11(16): 29632964.
3. Arnold, S., Kadenbach, B., 1997.
Cell respiration is controlled by
ATP, an allosteric inhibitor of
cytochrome-c oxidase. Eur J
Biochem. 249(1):350-4.
4. Bioinformatics,
2016.
HK2
Hexokinase 2 [Homo sapiens
(humans)]. NCBI. Gene ID: 3099.
5. N.d. Primary information of p53
gene.
Bioinformatics.
http://www.bioinformatics.org/p53/i
ntroduction.html
6. Bensinger, S.J., Christofk, H.R.,
2012. New aspects of the Warburg
effect in cancer cell biology.
Seminars in Cell and Developmental
Biology. 23, 352-361.
7. Cardenas, M.L., Bowden, A.C.,
Ureta, T., 1998. Evolution and
regulatory role of the hexokinases.
Science Direct.
8. Cenizo, L.S., Fromentini, L., Aldea,
M., Ortega, A.D., Huerta, P.G.,
Arago, M.S., Cuezva, J.M., 2010.
Up-regulation of the ATPase
Inhibitory Factor 1 (IF1) of the
Mitochondrial H+-ATP Synthase in

13

Human Tumors Mediates the
Metabolic Shift of Cancer Cells to a
Warburg Phenotype. J Biol Chem.
285(33): 25308-25313.
9. Chen, L., Liu, T., Zhou, J., Wang,
Y., Wang, X., Di, W., Zhang, S.,
2014. Citrate Synthase Expression
Affects Tumor Phenotype and Drug
Resistance in Human Ovarian
Carcinoma. PLOS.
10. Ciriolo, M.R. & Cardaci, S., 2012.
TCA Cycle Defects and Cancer:
When Metabolism Tunes Redox
State. International Journal of Cell
Biology. ID 161837.
11. Giri, D., 2016. Glycolysis: All Steps
with Diagram, Enzymes, Products,
Energy Yield and Significance.
www.Laboratoryinfo.com.
12. Graziano, F., Ruzzo, A., Giacomini,
E., Ricciardi,
T., Aprile,
G., Loupakis, F., 2016. Glycolysis
gene expression analysis and
selective metabolic advantage in the
clinical progression of colorectal
cancer. Pub Med.
13. Gupta, V., Bamezai, R.N.K., 2010.
Human pyruvate kinase M2: A
multifunctional protein. Protein
Science. 2031-2044.
14. Hanahan, D., Weinberg, R.A., 2011.
Hallmarks of Cancer: The Next
Generation. PubMed.
15. Hirchey, M.D., DeBerardinis, R.J.,
Diehl, A.M., Drew, J.E., Frezza, C.,
Green,
M.F.,
et.al,
2015.
Dysregulated metabolism contributes
to oncogenesis. Seminars in Cancer
Biology.
16. Icard. P., Poulain, L., Lincent, H.,
2012. Understanding the central role
of citrate in the metabolism of cancer
cells. BBA Reviews on Cancer.
17. Jones, R.G.,Thompson, C.B., 2009.
Tumor
suppressors
and
cell

metabolism: a recipe for cancer
growth. Genes and Development.
23(5): 537-548.
18. King, A., Sleak, M.A., Gottlieb, E.,
2006. Succinate dehydrogenase and
fumarate
hydratase
linking
mitochondrial dysfunction and caner.
Oncogene. 4675-4682.
19. Krieg,
R.C.,
Knuechel.
R.,
Schiffmann, E., Liotta, L.A.,
Petricoin III, E.F., Herrmann, P.C.,
2004. Mitochondrial proteome:
Cancer-altered
metabolism
associated with cytochrome c
oxidase subunit level variation.
Proteomics. 2789-2795.
20. Liu, Z.X., Hong, L., Fang, S.Q., Tan,
G.H., Huang, P.G., Zeng, Z., Xia, X.,
Wang, X.X., 2016. Overexpression
of pyruvate kinase M2 predicts a
poor prognosis for patients with
osteosarcoma. PubMed.
21. Lin, C.C., Cheng, T.L., Tsai, W.H.,
Tsai, H.J., Hu, K.H., Chang, H.C.,
et.al, 2012. Loss of the respiratory
enzyme citrate synthase directly
links the Warburg effect to tumor
malignancy. Scientific Reports.
22. Mazurek, S., Boschek, C.B., Hugo,
F., Eigenbrodt, E., 2005. Pyruvate
kinase type M2 and its role in tumor
growth and spreading. PubMed.
23. Modica-Napolitano, J.S., Weissig,
V., 2015. Treatment Strategies that
Enhance the Efficacy and Selectivity
of
Mitochondira-Targeted
Anticancer Agents. International
Journal of Molecular Sciences.
24. N.d. Krebs Cycle. Xamplified.
http://www.chemistrylearning.com/k
rebs-cycle/
25. N.d. Cancer Statistics. National
Cancer Institute.

14

26. N.d. Oxidative Phosphorylation.
Khan
Academy.
https://www.khanacademy.org/scien
ce/biology/cellular-respiration-andfermentation/oxidativephosphorylation/a/oxidativephosphorylation-etc.
27. N.d. Citrate Synthase. PDB-101.
http://pdb101.rcsb.org/motm/93
28. Patra, K.C., Wang, Q., Bhaskar, P.T.,
Miller, L., Wang, Z., Wheaton, W.,
et.al, 2013. Hexokinase 2 is required
for tumor initiation and maintenance
and its systemic deletion is
therapeutic in mouse models of
cancer. Cancer Cell.
29. Peng, Q., Zhou, J., Zhou, Q., Pan, F.,
Zhong, D., Liang, H., 2009.
Silencing hexokinase II gene
sensitizes human colon cancer cells
to 5-fluorouracil. Pub Med.
30. Primary information of p53 gene.
(n.d.). 2016.
31. Pratt, C. W., & Cornely, K., 2014.
Essential biochemistry. Hoboken,
NJ: Wiley.
32. Producer: Ken Burns, Writer:
Siddhartha
Mukherjee,
2015.
http://cancerfilms.org/
33. Serra, L.P., Marcilla, M., Villanueva,
A., Fernandez, R.A., Palau, A., Leal,
L., et.al, 2014. A DERL3-associated
defect in the degradation of SLC2A1
mediates the Warburg effect. PMC.
34. Srinivasan, S., Guha, M., Dong,
D.W., Whelan, K.A., Ruthel, G.,
Uchikado, Y., et.al, 2016. Disruption
of Cytochrome c Oxidase Function
Induces Warburg Effect and
Metabolic
Reprogramming.
Oncogene. 1585-1595.
35. Wang, Y., Yun, Y., Wu, B., Wen, L.,
Wen, M., Yang, H., et.al, 2016.
FOXM1 promotes reprogramming of
glucose metabolism in epithelial
ovarian cancer cells via activation of

GLUT1 and HK2 transcription.
Oncotarget.
36. Weinberg, R. A., 2014. The biology
of cancer. New York: Garland
Science, Taylor & Francis Group.
37. Whitford, D., 2005. Proteins:
Structure and function. Hoboken, NJ:
J. Wiley & Sons.
38. Wu, H., Yang, P., Hu, W., Wang, Y.,
Lu,
Y.,
Zhang,
L.,
2016.
Overexpression of PKM2 promotes
mitochondrial
fusion
through
attenuated p53 stability. PubMed.
39. Yuan, S., Qiao, T., Zhuang, X.,
Chen, W., Xing, N., Zhang, Q.,
2016. Knockdown of the M2 Isoform
of Pyruvate Kinase (PKM2) with
shRNA Enhances the Effect of
Docetaxel in Human NSCLC Cell
Lines In Vitro. Yonsei Med J. 131223.

